BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28705432)

  • 21. Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells.
    Liu CY; Su JC; Ni MH; Tseng LM; Chu PY; Wang DS; Tai WT; Kao YP; Hung MH; Shiau CW; Chen KF
    Breast Cancer Res Treat; 2014 Jul; 146(1):71-84. PubMed ID: 24903225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disulfiram suppresses cancer stem-like properties and STAT3 signaling in triple-negative breast cancer cells.
    Kim YJ; Kim JY; Lee N; Oh E; Sung D; Cho TM; Seo JH
    Biochem Biophys Res Commun; 2017 May; 486(4):1069-1076. PubMed ID: 28373070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
    Wu B; Fathi S; Mortley S; Mohiuddin M; Jang YC; Oyelere AK
    Bioorg Med Chem; 2020 Mar; 28(6):115345. PubMed ID: 32061484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Binding of galectin-1 to integrin β1 potentiates drug resistance by promoting survivin expression in breast cancer cells.
    Nam K; Son SH; Oh S; Jeon D; Kim H; Noh DY; Kim S; Shin I
    Oncotarget; 2017 May; 8(22):35804-35823. PubMed ID: 28415760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Silibinin downregulates MMP2 expression via Jak2/STAT3 pathway and inhibits the migration and invasive potential in MDA-MB-231 cells.
    Byun HJ; Darvin P; Kang DY; Sp N; Joung YH; Park JH; Kim SJ; Yang YM
    Oncol Rep; 2017 Jun; 37(6):3270-3278. PubMed ID: 28440514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy.
    Feng T; Cao W; Shen W; Zhang L; Gu X; Guo Y; Tsai HI; Liu X; Li J; Zhang J; Li S; Wu F; Liu Y
    Oncotarget; 2017 Jan; 8(1):329-344. PubMed ID: 27861147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combinatorial therapy for triple negative breast cancer using hyperstar polymer-based nanoparticles.
    Misra SK; Wang X; Srivastava I; Imgruet MK; Graff RW; Ohoka A; Kampert TL; Gao H; Pan D
    Chem Commun (Camb); 2015 Dec; 51(93):16710-3. PubMed ID: 26434941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/AKT signaling pathways.
    Wang S; Yao Y; Yao M; Fu P; Wang W
    Biochem Biophys Res Commun; 2018 Sep; 503(3):1605-1609. PubMed ID: 30072097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Sesquiterpenoid from Farfarae Flos Induces Apoptosis of MDA-MB-231 Human Breast Cancer Cells through Inhibition of JAK-STAT3 Signaling.
    Jang H; Ko H; Song K; Kim YS
    Biomolecules; 2019 Jul; 9(7):. PubMed ID: 31337063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Salidroside inhibits migration, invasion and angiogenesis of MDA‑MB 231 TNBC cells by regulating EGFR/Jak2/STAT3 signaling via MMP2.
    Kang DY; Sp N; Kim DH; Joung YH; Lee HG; Park YM; Yang YM
    Int J Oncol; 2018 Aug; 53(2):877-885. PubMed ID: 29901185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.
    Balko JM; Schwarz LJ; Luo N; Estrada MV; Giltnane JM; Dávila-González D; Wang K; Sánchez V; Dean PT; Combs SE; Hicks D; Pinto JA; Landis MD; Doimi FD; Yelensky R; Miller VA; Stephens PJ; Rimm DL; Gómez H; Chang JC; Sanders ME; Cook RS; Arteaga CL
    Sci Transl Med; 2016 Apr; 8(334):334ra53. PubMed ID: 27075627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cosmomycin C inhibits signal transducer and activator of transcription 3 (STAT3) pathways in MDA-MB-468 breast cancer cell.
    Kim J; Lee YJ; Shin DS; Jeon SH; Son KH; Han DC; Jung SN; Oh TK; Kwon BM
    Bioorg Med Chem; 2011 Dec; 19(24):7582-9. PubMed ID: 22071520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stress-induced EGF receptor signaling through STAT3 and tumor progression in triple-negative breast cancer.
    Balanis N; Carlin CR
    Mol Cell Endocrinol; 2017 Aug; 451():24-30. PubMed ID: 28088463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Osthole inhibits triple negative breast cancer cells by suppressing STAT3.
    Dai X; Yin C; Zhang Y; Guo G; Zhao C; Wang O; Xiang Y; Zhang X; Liang G
    J Exp Clin Cancer Res; 2018 Dec; 37(1):322. PubMed ID: 30577812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer.
    Gangrade A; Pathak V; Augelli-Szafran CE; Wei HX; Oliver P; Suto M; Buchsbaum DJ
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783777
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells.
    Don-Doncow N; Escobar Z; Johansson M; Kjellström S; Garcia V; Munoz E; Sterner O; Bjartell A; Hellsten R
    J Biol Chem; 2014 Jun; 289(23):15969-78. PubMed ID: 24755219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide.
    Lu L; Dong J; Wang L; Xia Q; Zhang D; Kim H; Yin T; Fan S; Shen Q
    Oncogene; 2018 Sep; 37(39):5292-5304. PubMed ID: 29855616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models.
    Handle F; Puhr M; Schaefer G; Lorito N; Hoefer J; Gruber M; Guggenberger F; Santer FR; Marques RB; van Weerden WM; Claessens F; Erb HHH; Culig Z
    Mol Cancer Ther; 2018 Dec; 17(12):2722-2731. PubMed ID: 30254184
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel potent azetidine-based compounds irreversibly inhibit Stat3 activation and induce antitumor response against human breast tumor growth in vivo.
    Yue P; Zhu Y; Brotherton-Pleiss C; Fu W; Verma N; Chen J; Nakamura K; Chen W; Chen Y; Alonso-Valenteen F; Mikhael S; Medina-Kauwe L; Kershaw KM; Celeridad M; Pan S; Limpert AS; Sheffler DJ; Cosford NDP; Shiao SL; Tius MA; Lopez-Tapia F; Turkson J
    Cancer Lett; 2022 May; 534():215613. PubMed ID: 35276290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
    Yu W; Li C; Zhang W; Xia Y; Li S; Lin JY; Yu K; Liu M; Yang L; Luo J; Chen Y; Sun H; Kong L
    J Med Chem; 2017 Apr; 60(7):2718-2731. PubMed ID: 28245116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.